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Abstract
Purpose Cyclin D1 has a central role in cell cycle control
and is an important component of estrogen regulation of
cell cycle progression. We have previously shown that high
cyclin D expression is related to aggressive features of ER-
positive but not ER-negative breast cancer. The aims of the
present study were to validate this differential ER-related
effect and furthermore explore the relationship between
cyclin D overexpression and CCND1 gene amplification
status in a node-negative breast cancer case–control study.
Methods Immunohistochemical nuclear expression of
cyclin D1 (n = 364) and amplification of the gene CCND1
by fluorescent in situ hybridization (n = 255) was per-
formed on tissue microarray sections from patients with
T1-2N0M0 breast cancer. Patients given adjuvant
chemotherapy were excluded. The primary event was
defined as breast cancer death. Breast cancer-specific sur-
vival was analyzed in univariate and multivariable models
using conditional logistic regression.
Results Expression of cyclin D1 above the median (61.7%)
in ER breast cancer was associated with an increased risk
for breast cancer death (OR 3.2 95% CI 1.5–6.8) also when
adjusted for tumor size and grade (OR 3.1). No significant
prognostic impact of cyclin D1 expression was found
among ER-negative cases. Cyclin D1 overexpression was
significantly associated to high expression of the prolifer-
ation markers cyclins A (q 0.19, p = 0.006) and B (q 0.18,
p = 0.003) in ER-positive tumors, but not in ER-negative
cases. There was a significant association between CCND1
amplification and cyclin D1 expression (p = 0.003), but
CCND1 amplification was not statistically significantly
prognostic (HR 1.4, 95% CI 0.4–4.4).
Conclusion We confirmed our previous observation that
high cyclin D1 expression is associated to high prolifera-
tion and a threefold higher risk of death from breast cancer
in ER-positive breast cancer.
Keywords Breast cancer  Proliferation  Cyclin D1 
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Introduction
Breast cancer is a heterogeneous disease. Decisions about
adjuvant treatment have traditionally been based upon
prognostic factors such as age, tumor size, histological
grade, proliferation, lymph node involvement, HER2 sta-
tus, estrogen receptor (ER), progesterone receptor (PgR),
and gene expression assays like Oncotype DX [1]. The
most commonly used proliferation marker in breast cancer
hitherto has been Ki-67, although problems of method
standardization cut-offs and reproducibility still remain [2].
Cyclin D1 is a member of the cyclin protein family
initiated during G1 and drives the G1/S phase transition.
Cyclin D1 binds to CDK4 and CDK6 and induces hyper-
phosphorylation of Rb, thereby promoting cellular prolif-
eration [3]. Aberrant cyclin D1 expression is common in
breast cancer [4]. Cyclin D1 expression has previously
been shown to correlate strongly to ER positivity and
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deregulation of cyclin D1 has been associated with resis-
tance to endocrine therapy in breast cancer cell lines [5, 6],
while the role of cyclin D1 overexpression and endocrine
resistance in the clinic is still controversial [5, 7–12]. The
corresponding gene CCND1 is amplified in approximately
9–30% in breast cancer [10, 13–16]. The importance of
improved understanding of cyclin D1 signaling in cancer
has recently been underscored due to the introduction of a
new class of antineoplastic drugs, the CDK 4/6 inhibitors
targeting cell cycle activation by cyclin D1 in breast cancer
and other malignant diseases [3].
A large number of previous studies have investigated the
prognostic impact of cyclin D1 expression or gene ampli-
fication in primary breast cancer [5, 7, 10–14, 16–49].
Most of these studies have used immunohistochemical
expression of the cyclin D1 expression [7, 10, 12, 13,
16–22, 25, 26, 28, 29, 31–42, 44, 45, 47–49], some mRNA
expression [5, 23, 29, 30, 46], some amplification of the
CCND1 gene [10, 11, 13, 14, 16, 24, 27, 43], and several
methods [10, 13, 16, 29]. There is still no consensus about
which method of assessment of cyclin D1 signaling aber-
rations is optimal. Studies, which have used several
methods of cyclin D1, have, however, shown the results of
these to be significantly positively correlated. Seven studies
have reported a significant positive association between
CCND1 gene amplification and protein expression in
addition to the present one [10, 13, 16, 28, 35, 38, 41].
Only one study [11] failed to find this association. A highly
significant correlation (q 0.43, p\ 0.0001) between cyclin
D1 mRNA and protein expression has also been reported
[29].
The prognostic impact of cyclin D1 amplification or
overexpression in unselected breast cancer has been
inconsistent; 10 studies reported cyclin D1 expression to be
a favorable prognostic marker [19, 25, 28, 32, 37–39, 41,
46, 49], 8 to be unfavorable [13, 14, 18, 26, 33, 34, 42, 44],
and 21 studies found no association [7, 11, 12, 16, 17,
20–24, 27, 29–31, 35, 36, 40, 43, 45, 47, 48].
Thirteen studies have studied the impact of cyclin D1
overexpression or gene amplification in ER-positive breast
cancer. Six studies [5, 7, 11, 18, 42, 44] reported high
cyclin D1 to be associated to higher risk of recurrence or
death, while the results were non-significant in 6
[12, 13, 17, 24, 31, 45]. One study, the transATAC study,
reported gene amplification to be of adverse prognostic
impact, while high expression of nuclear cyclin D1 was
favorable [10].
Six previous studies have analyzed the prognostic
impact of cyclin D1 in ER-negative breast cancer. Over-
expression was reported to be a favorable factor in two
[25, 37], unfavorable in one [45], and of no prognostic
impact in three studies [5, 17, 31].
In accordance with these previous inconsistent results,
the recent meta-analysis by Xiao-Ling found no overall
prognostic effect of cyclin D1 signaling aberrations when
ER-positive and ER-negative cases were analyzed together
[50]. However, cyclin D1 overexpression was consistently
and significantly associated to worse prognosis in ER-
positive cases.
We have previously demonstrated that high cyclin D1
expression is linked to increased proliferation in ER-posi-
tive breast cancer, while no association was seen in ER-
negative disease [17]. Moreover, high cyclin D1 expression
was related to shorter metastasis-free survival in patients
not receiving adjuvant chemotherapy.
The aim of this studywas to further explore the prognostic
effect of cyclin D1 aberrations in relation to ER status in a
patientmaterial designed for evaluation of prognostic factors
in early breast cancer. Furthermore,wewanted to explore the
association between the protein expression of cyclin D1 and
its corresponding gene, CCND1.
Patients and methods
The source population of the study was a defined cohort of
women diagnosed with breast cancer in the Uppsala-Öre-
bro region during 1993–2004 as previously described [51].
The inclusion criteria were tumor size B50 mm, no lymph
node metastases, and no adjuvant chemotherapy. From the
whole cohort of 900 patients, 190 cases and 190 controls
(n = 380) were chosen.
Sixteen cases were non-evaluable due to lack of tumor
material, leaving 364 samples for Cyclin D1 analyses. Two
hundred and fifty-five samples were evaluable for CCND1
amplification analyses (Fig. 1).
The study was approved by the local ethics committee in
Uppsala, Sweden.
TMA construction
Paraffin blocks from the patients’ primary tumors were
collected. Hematoxylin and eosin sections were reviewed
and areas with invasive tumor were selected. Representa-
tive areas from each tumor were punched and brought into
recipient paraffin blocks to construct TMAs consisting of
two cores (diameter 1 mm) of each tumor. 3–4-lm-thick
sections were cut from array blocks and transferred to glass
slides.
Immunohistochemistry
TMA slides were deparaffinized in xylene and rehydrated
through a ladder of graded ethanol (absolute ethanol, 95%,
80% and distilled water). For detection of cyclin D1 (RM-
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9104-S; NeoMarkers), antigen retrieval was performed in a
microwave oven for 10 min (750 W) ? 15 min (350 W)
with the use of a TE (Tris–EDTA pH9 buffer). After
antigen retrieval, all TMA slides were processed in an
automatic immunohistochemistry staining machine
according to standard procedures (Autostainer, Dako,
Sweden).
Evaluation of immunoreactivity scores
All cyclin D1 stainings were scored by one investigator
(Ahlin C) blinded to all clinical information during scoring.
Cells were manually counted in high-power fields. Only
unequivocal nuclear staining was accepted. Hot spots were
chosen for evaluation, and a minimum of 200 cells per
patient were counted. Staining procedure and scoring of
ER, PR, Ki-67, cyclin A, cyclin B, cyclin E, and HER2
have been described previously [51–53].
Fluorescence in situ hybridization (FISH) analysis
For two-color FISH analysis, 4-lm-thick TMA sections
were cut, mounted on positively charged glass slides (Su-
perfrostTM Plus, Thermo Fisher Scientific) and dried.
Sections were then deparaffinized in xylene, dehydrated in
absolute ethanol, and subsequently pretreated using a
commercial kit (Vysis paraffin pretreatment reagent kit,
Abbott molecular) whereby the slides were immersed in
pretreatment solution for 30 min at 80 C followed by
incubation in protease solution for 37 min at 37 C.
FISH analyses were performed using a dual-probe kit
containing an orange-labeled CCND1-specific and green-
labeled CEP 11 centromere probe (Vysis CCND1/CEP 11
FISH probe kit, Abbott molecular). Hybridization and post-
hybridization washes were performed according to the
manufacturer’s protocol. Slides were briefly dipped in
dH2O after being washed and ProLong
 Gold Antifade
900 patients identified from the 
Uppsala-Örebro breast cancer register 
fulfilling inclusion criteria 
480 patients randomly 
excluded  
Totally 480 patients 
    240 cases                            240 controls   
    died from BC                      alive 
Totally 380 tumors investigated 
190 cases                   190 controls 
Totally 364 evaluable for cyclin D1  
immunohistochemistry 
182 cases                   182 controls 
Totally 255 tumors available for analysis of 
CCND1 amplification 
128 cases                   127 controls 
125 tumors were not 
evaluable for CCND1 
amplification analyses 
50 cases were excluded due to 
failing inclusion criteria at 
hospital record review. The 
corresponding matched 
controls were also excluded   
16 tumors were not 
evaluable due to poor 
tumor material for  
cyclin D1 
immunohistochemistry 
Fig. 1 Flow chart diagram of study design
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Mountant with DAPI (Thermo Fisher Scientific) was
applied directly.
Gene-specific and centromere copy numbers were esti-
mated by counting C20 nuclei in two tissue cores per case
at 100x magnitude. A ratio of 1.8 or higher for CCND1/
CEP was classified as CCND1 amplification. All FISH
analyses were performed by one investigator (Embretsén-
Varro E.) blinded to all clinical information.
Statistical analyses
To obtain unbiased estimates of relative risk, controls were
selected by incidence density sampling, which involves
matching each case to a sample of those who were at risk at
the time of the case occurrence.
The loss of power in comparison with a complete
analysis of all cohort members is small since approxi-
mately 20% of the entire cohort was chosen as control and
all eligible women with an event were included. Condi-
tional logistic regression analysis was performed to esti-
mate the odds ratios (ORs) and confidence interval (CI)
using the proportional hazard regression procedure in sta-
tistical analysis software (IBM SPSS version 23).
Correlations of Ki 67, cyclin A, cyclin B, cyclin D, and
cyclin E to other clinicopathologic parameters were eval-
uated using Spearman’s correlation test. Cut-off values
used for cyclin A, cyclin B, cyclin E, and Ki 67 were
defined as the 7th decile as previously described [51–53].
The median (61.7%) was chosen as the cut-off point for
cyclin D1, but all analyses were performed also with cyclin
D1 as a continuous variable.
Results
Patient and tumor characteristics according to cyclin D1
status are shown in Table 1. Median cyclin D1 expression
was 61.7, 68.7% in ER-positive tumors and 34.3% in ER-
negative cases. The association between ER content (per-
cent nuclear staining) and high cyclin D1 was highly sig-
nificant (Table 2). Cyclin D1 expression was below 1% in
1 of 242 ER-positive cases (0.4%) and in 6 of 115 ER-
negative cases (6%). The distributions of cyclin D1 values
were different in ER-positive and ER-negative tumors.
Although overlapping, cyclin D1 peaked at 80% in ER-
positive and less than 5% in ER-negative tumors (Fig. 2).
Correlation between ER, cyclin D1,
and proliferation markers including grade
High cyclin D1 expression was significantly associated to
PgR positivity and lower grade (Table 1) and ER positivity
(Table 2) when ER-positive and ER-negative cancers were
tested together. The associations to PgR positivity and low
grade were significant only in ER-negative tumors.
A high ER receptor content was significantly associ-
ated to low tumor grade, low Ki-67 expression, and low
levels of cyclins A, B, and E. In contrast, cyclin D1
showed a positive correlation to ER receptor content
(Table 2).
In ER-positive tumors, high cyclin D1 expression
showed a significant correlation to high expression of
cyclin A and cyclin B. The correlations between cyclin D1
and other proliferation-associated factors were weakly and
mostly non-significantly negative in ER-negative tumors
(Table 2). The negative correlation between cyclin D1 and
cyclin E in ER-negative tumors, however, reached signif-
icance (q -0.21, p = 0.025).
Prognostic effect of cyclin D1 expression
Cyclin D1 expression was not significantly associated to
breast cancer mortality in the study population when ER-
positive and ER-negative cases were analyzed together
(OR 0.94, 95% CI 0.63–1.4, p = 0.76).
However, in the ER-positive group, high cyclin D1
expression had a significant and strong negative effect on
breast cancer mortality in both univariable (OR 3.2) and
multivariable (OR 3.1) analyses (Table 3). Cyclin D1
expression remained significantly associated to breast
cancer mortality in ER-positive cases also when analyzed
as a continuous variable in univariable (p = 0.01) and
multivariable (p = 0.03) analyses (data not shown).
The prognostic effect of cyclin D1 expression in ER-
positive cases was seen both in patients with (OR 2.0, 95%
CI 0.37–10.9, p = 0.4, n = 77) and without (OR 4.0, 95%
CI 1.1–14.2, p = 0.03, n = 165) adjuvant endocrine
therapy.
CCND1
The median (1.13) and mean (1.24) values of CCND1 copy
number were close to 1 in most cases. No tumor had a
quotient clearly less than 1. Only five tumors had a value
smaller than 1, and the lowest quotient was 0.91. Fourteen
tumors (5%) had a quotient higher than or equal to 1.8 and
were considered to have amplification of the CCND1 gene.
The highest quotient was 4.35.
Correlation of CCND1 amplification and tumor
characteristics
There was a statistically significant association between
CCND1 amplification and high expression of cyclin D1
(p = 0.003). Mean cyclin D1 expression was 55% in
tumors with normal copy number of CCND1 and 78% in
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the 14 amplified cases. A significant association between
CCND1 amplification and cyclin D1 expression was found
in both ER-positive (p = 0.003) and ER-negative tumors
(p = 0.05). No significant association was found between
gene amplification and tumor grade or proliferation mark-
ers (Table 4).
Prognostic effect of CCND1 amplification
CCND1 amplification had no significant prognostic impact
on breast cancer mortality in all cases together (OR 1.4,
95% CI 0.4–4.4, p value 0.56) or in ER-positive and ER-
negative cases separately (data not shown).
Table 2 Correlation of ER and cyclin D1 to grade and proliferation markers
ER %, all patients D1, all patients D1 ER-pos. group n = 242 D1 ER-neg. group n = 115
qb p value q p value q p value q p value
Ki 67a 20.17 0.001 20.18 0.001 0.08 0.241 20.12 0.221
Histological gradeb 20.30 \0.001 20.18 0.001 0.02 0.795 20.15 0.110
Cyclin Aa 20.30 \0.001 20.13 0.013 0.18 0.006 20.08 0.400
Cyclin Ba 20.23 \0.001 20.10 0.053 0.19 0.003 20.12 0.216
Cyclin Ea 20.24 \0.001 20.17 0.001 0.11 0.084 -0.21 0.025
Cyclin D1 0.40 \0.001
a Pearson correlation
b Spearman correlation
References Ahlin [51], Nimeus-Malmstrom [52], Lundgren[53]
Significant associations (p\ 0.05) in bold
Fig. 2 Distribution of nuclear cyclin D1 expression according to ER status
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Discussion
In a previous study in unselected cases of breast cancer, we
found that the prognostic impact of cyclin D expression
was dependent on ER receptor status [17]. In ER receptor-
positive disease, high cyclin D expression was associated
to high proliferation and other markers of tumor aggres-
siveness, while the opposite was true in ER-negative cases.
Moreover, high cyclin D1 was a significant adverse prog-
nostic factor for metastasis-free survival in chemotherapy-
naı̈ve patients with ER-positive tumors. The primary aim of
the present study was to confirm these findings. Addition-
ally, since amplification of the cyclin D gene CCND1 is
one of the reasons for high cyclin D1 expression in breast
cancer, we also studied the copy number of CCND1, and
its association to cyclin D1 expression and prognosis.
The patients included in this study [51] were selected
from the regional cancer registry of Uppsala-Örebro region
in order to optimize the analysis of prognostic markers,
especially cyclins and other proliferation markers in early
breast cancer. Cases given adjuvant chemotherapy were
excluded, since there is evidence that adjuvant
chemotherapy may interfere with the prognostic effect of
proliferation, possibly due to a better effect of
chemotherapy in proliferating cells [17, 54].
Cyclin D1 expression was strongly associated to ER
positivity in accordance with numerous previous reports
[5, 12, 13, 15, 19, 27, 28, 31, 37–41, 43, 45–47, 49, 55–58].
Many cases with high cyclin D1 expression were never-
theless also found in ER-negative tumors. Low expression of
cyclin D1was almost exclusively seen in ER-negative cases.
This study confirms that the prognostic impact of cyclin
D1 expression indeed depends on ER status. High
expression increased breast cancer mortality in ER-positive
cases, while no significant impact was seen in ER-negative
cases. In ER-positive cases, cyclin D1 expression was
significantly associated to markers of high proliferation
including cyclins A and B. No such association was found
in ER-negative tumors. On the contrary, like in our pre-
vious study [17], there was even an inverse association
between the expression of the cyclins D1 and E. An early
study by Kenny et al., analyzing cyclin D1 mRNA
expression, came to similar conclusions, showing that
cyclin D1 mRNA levels were significantly associated to
relapse and breast cancer death in ER-positive disease,
while no association was found in ER-negative disease [5].
This indicates that high cyclin D1 expression is linked to an
activated cell cycle and worse prognosis of breast cancer in
ER-positive disease, while cyclin D1 expression does not
associate to markers of cell cycle activation or prognosis in
ER-negative tumors. Many previous studies focusing on
ER-positive breast cancer have found high cyclin D1
expression or gene amplification to be an adverse prog-
nostic sign [5, 7, 11, 18, 42, 44, 50], while the results in
ER-negative and in unselected breast cancer patients have
been highly inconsistent. For further details, see the
Introduction section.
One study, the TransATAC study, has reported results
partly at odds with our results and other studies on ER-
positive breast cancer [10]. The TransATAC study is a
biomarker study on histological samples collected from
patients participating in the ATAC trial, which is a ran-
domized trial comparing anastrozole to tamoxifen adju-
vant treatment in primary breast cancer. In the
TransATAC study, cases with high cyclin D1 expression
had a significantly longer time to recurrence and better
overall survival in both univariable and multivariable
analyses. However, like our study high expression of
cyclin D1 was associated to gene amplification of the
CCND1 and a high proliferation assessed by Ki-67 IH.
Both Ki-67 expression and CCND1 gene amplification
were, in contrast to cyclin D1 IH expression, associated to
a worse outcome. The reason for these partly internally
inconsistent associations and the difference between the
results of the TransATAC study and those of our as well
as the meta-analysis study are not obvious nor did the
authors of the TransATAC publication suggest any
explanation. TransATAC is by far the largest published
study of cyclin D1 signaling and breast cancer prognosis
(n = 1155). Thus, it is improbable that these discrepancies
are due to chance alone. Several differences between the
TransATAC and the current studies may offer at least a
partial explanation. In contrast to our study, all patients
received adjuvant endocrine treatment. Although the
TransATAC analysis was restricted to ER-positive cases,
the definition of ER positivity was based on the Allred
score with a cut-off for positivity of 2, which corresponds
to as few as 1–10% weakly positive cells [59, 60]. In our
studies, we used a cut-off of 10% according to Scandi-
navian practice and the results of the EBCTCG meta-
analysis [61]. Visual inspection of the cumulative recur-
rence rate curves in the TransATAC study indicated that
high recurrence rate in cases with very low cyclin D1
expression (\1%) seems to account for most of the
prognostic impact of cyclin D1 expression. In our study,
most of the cases with cyclin D1 expression below 1%
were ER negative. Thus, one may speculate that one
reason for the discrepancy may be different ER receptor
classification. Interestingly, the curves depicting the
recurrence rate in cases with cyclin D1 expression 1–9%,
10–30%, 30–67%, and[67% in the TransATAC did not
show any orderly linear association between prognosis and
cyclin D1 expression level. Patients with totally negative
cyclin D1 expression had the worst prognosis. However,
Breast Cancer Res Treat (2017) 164:667–678 673
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the second worst prognosis was found in patients having
high, 30–67%, cyclin D1 expression. This suggests that
the association between cyclin D1 and prognosis in ER-
positive breast cancer may not be simply linear.
A Swedish study investigating cyclin D1 and benefit of
adjuvant tamoxifen may support this interpretation; the
benefit of adjuvant tamoxifen was restricted to the group
with intermediate cyclin D1 expression, and these patients
had the best prognosis while the patients with either very
high or low cyclin D1 expression did not benefit and had a
worse prognosis after endocrine treatment [12].
In conclusion, despite the partly discordant results of the
large transATAC study, most previous analyses of the
impact of cyclin D1 expression in ER-positive breast
cancer have, like the present one, shown high expression to
be a sign of tumor aggressiveness and poor prognosis.
A few previous studies have suggested that high cyclin
D1 expression may be associated to tamoxifen resistance
[7, 42], which might partly explain the negative impact of
cyclin D1 in ER-positive breast cancer. We therefore tested
the prognostic impact of cyclin D1 expression separately in
patients treated or not with adjuvant tamoxifen, but found
no indication that the prognostic effect was restricted to
adjuvant tamoxifen use; on the contrary, the impact of
cyclin D1 expression was even stronger in the group that
has not received hormonal treatment. This issue is still
controversial, since some studies have found cyclin D1
overexpression to be associated to tamoxifen resistance
[5, 7, 8, 12], some to improved effect of endocrine treat-
ment [7–9, 42], and some studies found no association
[10, 11]. Although we cannot exclude the possibility that
part of the negative impact of cyclin D1 overexpression
might be explained by endocrine treatment resistance, the
significant association between high cyclin D1 expression
and aggressive biological features of the tumor at diagnosis
indicates that adjuvant treatment resistance cannot be the
only explanation.
The proportion of patients with amplification of CCND1
in the present study was low (5%), in accordance with
previous large studies (n = 613, 738, 1155) where between
8.7 and 10% of cases have been found to have amplifica-
tion [10, 13, 14]. Other smaller studies (n = 93, 117) have
published higher frequencies of CCND1 amplification,
24.4 and 30%, respectively [15, 16]. Amplification of
CCND1 thus seems to explain only a small part of cases
with high cyclin D1 expression. We did not find CCND1
amplification prognostic possibly due to statistical power,
since the number of amplified cases was low and confi-
dence levels were wide (1.4, 95% CI 0.4–4.4). Seven
previous studies have tested the prognostic impact of
CCND1 amplification, of which two reported a significant
association between amplification and worse prognosis
[10, 14], one reported a significant association in ER-pos-
itive cases only [13], while five studies failed to find a
significant association [11, 16, 24, 27, 43].
Our results support previous studies on the close link
between ER signaling and cyclin D1 in cell cycle activation
[62]. Moreover, a recent publication [63] demonstrated that
cyclin D1 overexpression increased stem cell-like behavior
and migration in ER-positive breast cancer cell lines, while
the opposite was true in ER-negative cells [17], indicating
that the effect of cyclin D1 expression in ER-positive and
ER-negative breast cancer may be fundamentally different.
Inhibition of the cyclinDkinases CDK4/6 by palbociclib had
selective antitumor efficacy in ER-positive cell lines, while
non-luminal/basal subtypes were resistant [64].
Our results may have implications for drugs targeting
cyclin D1. The first phase III studies on the CDK4/
Table 3 Uni- and multivariable analyses of breast cancer mortality
Univariable analysis Multivariable analysis (adjusted for tumor size, grade, and
adjuvant endocrine treatmenta)
OR 95% CI p value OR 95% CI p value
ER-positive group n = 242
Cyclin D1 (reference B median, 61.7%) 3.2 1.5–6.8 0.002 3.1 1.3–7.1 0.009
Tumor size (cm) 1.9 1.2–3.1 0.009 2.3 1.2–4.2 0.01
Elston grade 2.6 1.3–5.0 0.005 2.6 1.2–5.5 0.01
Adjuvant endocrine treatment (reference: none) 0.8 0.4–1.6 0.49 0.4 0.2–1.1 0.07
ER-negative group (n = 115)
Cyclin D1 (reference B median, 61.7%) 0.25 0.03–2.2 0.58 0.3 0.1–2.4 0.23
Tumor size (cm) 1.6 0.6–3.9 0.34 1.6 0.6–4.3 0.31
Elston grade 1.2 0.5–2.8 0.67 1.2 0.5– 3.0 0.77
CI confidence interval, OR odds ratio
a For endocrine treatment in ER-positive group only
Reference Ahlin [51]
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inhibitors palbociclib [65, 66] or ribociclib [67] have
shown impressive results in ER-positive breast cancer
combined with letrozole [66, 67] or fulvestrant [65]. We
have found only little data concerning the effect of CDK4/6
inhibition in ER-negative breast cancers; a phase II study
of palbociclib monotherapy in advanced heavily pretreated
breast cancer recruited four cases with triple-negative dis-
ease, none of which experienced a response [68].
In conclusion, this study showed that high expression of
cyclin D1 is associated to cell cycle activation and poor
prognosis in ER-positive tumors only. High cyclin D1
expression was significantly linked to the expression of ER
and gene amplification of CCND1, although only a small
proportion of cases overexpressing cyclin D1 could be
attributed to gene amplification. Although a substantial
proportion of ER-negative tumors also express high levels
of cyclin D1, the biological role of cyclin D1 signaling in
tumors lacking ER, if any, remains to be explored.
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